These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 16301192)
1. Newer drug treatments: their effects on fracture prevention. Geusens P; Reid D Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):983-9. PubMed ID: 16301192 [TBL] [Abstract][Full Text] [Related]
2. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review. Gallacher SJ; Dixon T Calcif Tissue Int; 2010 Dec; 87(6):469-84. PubMed ID: 20872215 [TBL] [Abstract][Full Text] [Related]
3. How to manage postmenopausal osteoporosis? Body JJ Acta Clin Belg; 2011; 66(6):443-7. PubMed ID: 22338309 [TBL] [Abstract][Full Text] [Related]
5. EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis. Palacios S; Brincat M; Erel CT; Gambacciani M; Lambrinoudaki I; Moen MH; Schenck-Gustafsson K; Tremollieres F; Vujovic S; Rees M; Rozenberg S Maturitas; 2012 Feb; 71(2):194-8. PubMed ID: 22176952 [TBL] [Abstract][Full Text] [Related]
6. Developments in the pharmacotherapeutic management of osteoporosis. Close P; Neuprez A; Reginster JY Expert Opin Pharmacother; 2006 Aug; 7(12):1603-15. PubMed ID: 16872263 [TBL] [Abstract][Full Text] [Related]
7. Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls. Cremers S; Garnero P Drugs; 2006; 66(16):2031-58. PubMed ID: 17112299 [TBL] [Abstract][Full Text] [Related]
9. New approaches to the treatment of osteoporosis. Silva BC; Bilezikian JP Annu Rev Med; 2011; 62():307-22. PubMed ID: 21054170 [TBL] [Abstract][Full Text] [Related]
10. Effect of osteoporosis treatment on mortality: a meta-analysis. Bolland MJ; Grey AB; Gamble GD; Reid IR J Clin Endocrinol Metab; 2010 Mar; 95(3):1174-81. PubMed ID: 20080842 [TBL] [Abstract][Full Text] [Related]
11. [New bone density conservation agents for osteoporosis under research and development: Strontium ranelate]. Shiraki M Nihon Rinsho; 2007 Nov; 65 Suppl 9():447-53. PubMed ID: 18161147 [No Abstract] [Full Text] [Related]
12. [Newly developed drugs for osteoporosis in overseas and their future roles for the therapy]. Wada S; Fukawa T; Kamiya S Clin Calcium; 2008 Oct; 18(10):1483-92. PubMed ID: 18830046 [TBL] [Abstract][Full Text] [Related]
13. Treatment of osteoporosis in women intolerant of oral bisphosphonates. Aspray TJ; Francis RM Maturitas; 2012 Jan; 71(1):76-8. PubMed ID: 22079368 [TBL] [Abstract][Full Text] [Related]
14. [Drugs under development for osteoporosis ]. Masuda H; Tanaka S Nihon Rinsho; 2009 May; 67(5):980-4. PubMed ID: 19432120 [TBL] [Abstract][Full Text] [Related]
15. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. Wensel TM; Iranikhah MM; Wilborn TW Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432 [TBL] [Abstract][Full Text] [Related]
16. [Up-to-date treatments for osteoporosis]. Bors K Orv Hetil; 2006 Feb; 147(7):301-6. PubMed ID: 17489157 [TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapies to manage bone loss-associated diseases: a quest for the perfect benefit-to-risk ratio. Valverde P Curr Med Chem; 2008; 15(3):284-304. PubMed ID: 18288984 [TBL] [Abstract][Full Text] [Related]
18. [[Antiresorptive agents in the treatment of osteoporosis]. Novak S Reumatizam; 2014; 61(2):89-94. PubMed ID: 25427401 [TBL] [Abstract][Full Text] [Related]
19. The relative merits of anabolics versus anti-resorptive compounds: where our targets should be, and whether we are addressing them. Gasser JA Curr Opin Pharmacol; 2006 Jun; 6(3):313-8. PubMed ID: 16650802 [TBL] [Abstract][Full Text] [Related]
20. Strontium ranelate: new perspectives for the management of osteoporosis. Cortet B Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv1-2. PubMed ID: 19783588 [No Abstract] [Full Text] [Related] [Next] [New Search]